Microbiome Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for microbiome dealmaking

Microbiome partnering is driven by emerging science and novel therapeutic approaches, with deal structures reflecting platform-based technologies, live biotherapeutics, and data-driven discovery.

This report provides a comprehensive and structured analysis of 250+ microbiome collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how microbiome deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by platform type, application, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a highly innovative and still-evolving therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within microbiome partnerships, particularly in areas involving novel mechanisms of action and emerging clinical validation.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark emerging technology transactions
Prepare for negotiations with well-defined market context
Evaluate platform partnerships and collaboration opportunities
Support internal strategy with robust, defensible data
What's included
250+ microbiome collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, platform, and application)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for microbiome dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how microbiome partnerships are structured, negotiated, and valued.

Product Code: CP2121

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in microbiome dealmaking

2.1. Introduction
2.2. Microbiome deals over the years
2.3. Most active microbiome dealmakers
2.4. Microbiome deals by deal type
2.5. Microbiome deals by therapy area
2.6. Microbiome deals by industry sector
2.7. Deal terms for microbiome deals
- 2.7.1 Microbiome deals headline values
- 2.7.2 Microbiome deal upfront payments
- 2.7.3 Microbiome deal milestone payments
- 2.7.4 Microbiome royalty rates

Chapter 3 - Leading microbiome deals

3.1. Introduction
3.2. Top microbiome deals by value

Chapter 4 - Most active microbiome dealmakers

4.1. Introduction
4.2. Most active microbiome dealmakers
4.3. Most active microbiome deals company profiles

Chapter 5 - Microbiome contracts dealmaking directory

5.1. Introduction
5.2. Microbiome contracts dealmaking directory

Chapter 6 - Microbiome dealmaking by technology type

Deal directory
Deal directory - Microbiome deals by company A-Z
Deal directory - Microbiome deals by deal type
Deal directory - Microbiome deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Microbiome deals since 2016
Figure 2: Active microbiome dealmaking activity since 2016
Figure 3: Microbiome deals by deal type since 2016
Figure 4: Microbiome deals by therapy area since 2016
Figure 5: Microbiome deals by industry sector since 2016
Figure 6: Microbiome deals with a headline value
Figure 7: Microbiome deals with an upfront value
Figure 8: Microbiome deals with a milestone value
Figure 9: Microbiome deals with a royalty rate value
Figure 10: Top microbiome deals by value since 2016
Figure 11: Most active microbiome dealmakers since 2016
Figure 12: Microbiome deals by technology type since 2016